Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy (AOITC)

17 septembre 2026 mis à jour par: AO Innovation Translation Center

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy: A Multi-center Retrospective Cohort Study

Osteoradionecrosis (ORN) of the jaw is a serious complication that can occur after radiation therapy for head and neck cancers, including oral cavity cancer (OCC). ORN happens when jawbone tissue dies and fails to heal, often triggered by dental issues like tooth extractions or poorly fitting dentures. Symptoms can include exposed bone, pain, difficulty opening the mouth, trouble swallowing, and even jaw fractures-leading to major physical and emotional challenges.

The likelihood of ORN varies widely, from less than 1% to over 50% in head and neck cancer patients. For OCC specifically, studies report rates from 4% up to 25%. Treatment depends on how much bone is affected and can range from medication to major surgery.

Risk factors include radiation dose, tumor location, oral health, dental extractions, lifestyle habits (like alcohol use), and other health conditions. Poor oral hygiene, high radiation doses, and alcohol use are among the most common risks. However, current data on OCC patients is limited and often not broadly applicable.

This study will retrospectively examine what increases the risk of ORN in OCC patients who received radiation therapy before or after surgery. Using data from multiple international centers, it aims to identify patterns and provide globally relevant insights. The results will help guide prevention strategies and create evidence-based guidelines to reduce ORN and improve long-term outcomes for these patients.

Aperçu de l'étude

Type d'étude

Observationnel

Inscription (Estimé)

1000

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients will be selected from the primary care center where the patients received their initial treatment and followed up for at least 24months

La description

Inclusion Criteria:

  • Adults (≥18 years) diagnosed with OCC and treated with radiotherapy with curative intent (preoperative or/and postoperative, not palliative; definitive RT)
  • Patients who completed the full prescribed radiotherapy course; patients remain eligible if radiotherapy was discontinued due to suspected and subsequently confirmed ORN
  • Available, complete medical records including RT details, oral status, comorbidities, dental procedure details (as applicable), and lifestyle factors (as applicable)
  • Documented informed consent from the treated patient, where applicable, permitting the use of their medical records for research purposes, in accordance with the requirements of the Institutional Review Board (IRB) or Ethics Committee (EC).
  • Availability of at least 24 months of follow-up data after completion of radiotherapy, or follow-up until the occurrence of ORN, death, or loss to follow-up, whichever occurs first.
  • Completion of the radiotherapy course on or before 31 December 2024.

Exclusion Criteria:

  • Patients with non-oral cavity primary cancers (eg, oropharynx, larynx)
  • Patients treated only with surgery or conservatively, without any form of RT
  • Incomplete or missing medical records
  • Record of use of antiresorptive (eg, bisphosphonate, denosumab) and antiangiogenic drugs
  • Patients with jaw necrosis attributable to non-radiation-related causes, such as medication-related osteonecrosis of the jaw (MRONJ), trauma, or odontogenic infections
  • Patients with known metastatic bone disease in the jaw
  • Patients who discontinued radiotherapy for reasons unrelated to ORN suspicion or confirmation (eg, death, dropout, treatment intolerance, or other non-ORN related causes)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: RETROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Cases (ORN group)

Developed clinically and radiographically or histologically confirmed osteoradionecrosis (ORN) of the jaw following radiotherapy.

Control (non-ORN group)

No clinical, radiological, or histological diagnosis of ORN during the follow-up period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Development of osteoradionecrosis (ORN) of the jaw
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

The primary outcome is the development occurrence (yes/no) of ORN after completion of pre- and/or postoperative RT. The objective is to identify and evaluate patient-, tumor-, treatment-, and region-related risk factors associated with the development of ORN across multiple geographic regions.

Scoring Scale:

The primary endpoint will be treated as a binary variable:

0 = No ORN

1 = Development of ORN Time to ORN onset (interval between completion of RT and clinical diagnosis of ORN) will also be recorded for time-to-event analyses.

After completion of pre-and/or postoperative radiotherapy up to 24 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of ORN Across Geographic Regions
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence rates across geographical regions, namely between the Eastern and Western world, and High-Income Countries versus Low and Middle-Income Countries.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Severity of ORN by Tumor Characteristic
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate the variability in the severity of osteoradionecrosis (ORN) based on primary tumor site (eg, tongue, floor of mouth, oral tongue, buccal mucosa, gingiva), histological tumor type (eg, adenoid cystic carcinoma, squamous cell carcinoma), and tumor characteristics including size, clinical stage (T1-T4), overall stage (III-IVA), and nodal status (N0, N1-2B, N2C, N3

After completion of pre-and/or postoperative radiotherapy up to 24 months
Association between radiotherapy dose and ORN severity
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To investigate the association between radiotherapy dose parameters (total dose and duration) and the severity grade of ORN among patients who develop ORN. Is there a correlation between increased radiation dose and duration and the severity of the condition?

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence and severity comparison of preop vs. postop RT
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence and severity of ORN in patients undergoing preoperative versus postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence comparison across RT modalities
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence ORN across different radiation modalities, including intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and conventional three-dimensional conformal radiotherapy (3D-CRT)

After completion of pre-and/or postoperative radiotherapy up to 24 months
To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Complication evaluation with pre- or postop RT
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate potential complications associated with preoperative and postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN

After completion of pre-and/or postoperative radiotherapy up to 24 months
To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT
Délai: After completion of pre-and/or postoperative radiotherapy up to 24 months

To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT

After completion of pre-and/or postoperative radiotherapy up to 24 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Khalid Abdel-Galil, MD, Hamad Medical Corporation PO Box 3050 Doha, Qatar

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 mars 2027

Achèvement primaire (Estimé)

15 juin 2029

Achèvement de l'étude (Estimé)

15 juillet 2029

Dates d'inscription aux études

Première soumission

27 juillet 2026

Première soumission répondant aux critères de contrôle qualité

17 septembre 2026

Première publication (Réel)

23 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 septembre 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner